Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →CHIP-AML22 is a multinational pediatric de novo AML trial protocol integrating risk-adapted therapy, randomized gemtuzumab ozogamicin and consolidation-course comparisons, subgroup-specific quizartinib, and toxicity-reduction measures.
The protocol tests whether adding quizartinib for FLT3-ITD+/NPM1wt AML, adding gemtuzumab ozogamicin for CD33-positive AML, and refining treatment intensity through MRD and genetic risk stratification can improve disease control while consolidation reduction and dexrazoxane may limit toxicity; the supplied record reports the trial design, not efficacy or safety outcomes.
In 174 adults with stage III, HER2-negative, homologous-recombination-deficient breast cancer, this phase 3 trial found similar estimated 4-year overall survival with intensified alkylating chemotherapy plus autologous stem-cell rescue and with conventional chemotherapy followed by olaparib, while intensified treatment caused substantially more severe hematologic toxicity and serious adverse events.
Evidence: intensified chemotherapy with stem-cell rescue showed no overall-survival advantage over chemotherapy followed by olaparib and produced greater toxicity in this HRD-selected population; inference: HRD-guided use of the less intensive olaparib-containing strategy could avoid transplant-level treatment burden without sacrificing survival, but the wide hazard-ratio confidence interval and absence of a stated non-inferiority design prevent concluding equivalence.
In a multinational retrospective cohort of molecularly classified infant SHH medulloblastoma, progression-free survival and the prognostic relevance of biomarkers varied by upfront therapy, with high-dose or intraventricular methotrexate chemotherapy-only regimens showing PFS comparable to CSI-based treatment and better PFS than standard-dose chemotherapy-only regimens.
The evidence supports therapy-specific risk stratification and suggests that intensified chemotherapy-only strategies may preserve favorable disease control while avoiding upfront craniospinal irradiation in selected infants; whether either strategy reduces long-term toxicity without compromising cure requires prospective comparative trials and quality-of-life assessment.
In a multinational retrospective cohort of 375 young children with methylation-classified non-WNT/non-SHH medulloblastoma, survival differed by upfront treatment and molecular subgroup, including favorable chemotherapy-only outcomes for MBGroup3 subgroup 4 and very poor outcomes for MYC-amplified MBGroup3 subgroup 2 or 3.
The reported associations support testing biomarker-stratified treatment: high-dose chemotherapy might permit irradiation-sparing control in selected MBGroup3 subgroup 4 tumors, whereas MYC-amplified subgroup 2 or 3 disease likely requires alternative or intensified strategies; these are trial hypotheses rather than evidence of causal treatment benefit or established care.
In this multicentre, single-arm phase 2 cohort, single-agent inotuzumab ozogamicin produced responses in 22 of the first 31 evaluable children (71%) with CD22-positive, very high-risk first B-cell acute lymphoblastic leukaemia relapse, with substantial haematologic toxicity and sinusoidal obstructive syndrome in four of 23 transplanted patients.
The trial provides preliminary evidence that inotuzumab ozogamicin can serve as active reinduction therapy in CD22-positive very high-risk first paediatric B-ALL relapse; it is reasonable to hypothesize that this could facilitate subsequent curative treatment, but comparative benefit, durability of response, and effects on survival are not established by this single-arm report.
In the 233-patient randomized phase 2 BIOMEDE trial, adding erlotinib, dasatinib, or everolimus to radiotherapy did not improve overall survival relative to a historical temozolomide-treated cohort, although everolimus had lower toxicity and mTOR-pathway alterations or activation were associated with better response to everolimus.
The trial does not support broad use of these targeted agents in DIPG; however, the reported association between mTOR-pathway status and everolimus response suggests—without establishing—that molecular selection could identify a subgroup more likely to benefit from mTOR inhibition plus radiotherapy in future trials.
In this global phase 3 trial of 899 randomized adults with previously untreated high-risk DLBCL or HGBL, adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival but increased grade 3 or higher and fatal treatment-emergent adverse events, while overall-survival results remained immature.
The trial provides evidence that adding anti-CD19 tafasitamab and lenalidomide to first-line R-CHOP can reduce the risk of progression or death in high-risk adult DLBCL or HGBL; it remains an inference that this benefit will translate into longer overall survival or a favorable net clinical benefit, and the supplied record does not establish efficacy or safety in pediatric patients.
This meta- and network meta-analysis of 16 trials involving 1,602 participants with Hodgkin lymphoma reports pooled response rates and suggests differential response rankings for camrelizumab, dual-checkpoint inhibition, and checkpoint inhibitors combined with conventional therapy.
The reported comparative response signals support the hypothesis that selected PD-1/PD-L1 inhibitor combinations may improve response rates in Hodgkin lymphoma; however, this is an inference from aggregate and network comparisons, not proof of superiority, safety, survival benefit, or pediatric-specific efficacy.
In this phase 2 study, CFZ-VXLD did not significantly improve post-induction complete remission versus a weighted external real-world control in pediatric relapsed/refractory ALL, although overall response favored CFZ-VXLD in the B-ALL subgroup.
The reported B-ALL overall-response signal suggests that adding carfilzomib to VXLD may benefit a selected subset of heavily pretreated pediatric patients, but this is an inference requiring confirmation because the primary complete-remission endpoint was negative and comparisons relied on an external control.
In a single-center assessor-blinded randomized trial of 280 women aged 18–75 receiving adjuvant radiotherapy for breast cancer in China, structured education plus entertainment therapy was associated with a modest improvement in anxiety trajectory through six months, while the depression result was marginal.
The trial provides evidence that this psychosocial intervention may reduce anxiety during and after breast-cancer radiotherapy; extension to pediatric oncology is only an inference because no pediatric-specific population or subgroup results are reported.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 90.8/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 69.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 90.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 71.1; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 90.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 100.0; sample size: 30.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 90.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 99.8; sample size: 30.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 89.9/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 79.3; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 89.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 96.1; sample size: 50.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 89.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 77.8; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 89.4/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 92.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 89.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 89.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 60.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
